查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1571652

思觉失调症药物市场规模、份额、趋势分析报告：按类别、治疗、分销管道、地区和细分市场预测，2024-2030 年

Schizophrenia Drugs Market Size, Share & Trends Analysis Report By Class (Second-Generation Antipsychotics, Third-Generation Antipsychotics, Others), By Treatment, By Distribution Channels, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

思觉失调症药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球思觉失调症药物市场规模预计将达到112亿美元，2024年至2030年复合年增长率为5.3%。

总体而言，思觉失调症市场预计将受到药物传递技术的改进、长效注射剂（LAI）的可用性以及寻求治疗的患者数量增加的推动。支持新药广泛使用的主要特征可能是起效快、患者容易取得、效率高、患者依从性高。

思觉失调症对患者、患者家庭和整个社会带来沉重负担。患者和医生对精神疾病，特别是思觉失调症的认识的提高可能会增加新药的市场渗透率。目前，第二代和第三代抗精神病药物占据了很大的市场占有率。临床试验中的管道药物旨在透过阻断血清素和多巴胺受体的特定亚型来减轻症状，调节升高的多巴胺水平，甚至改善记忆力。

思觉失调症市场的成长主要是由旨在治疗思觉失调症症状的后期研发线产品的出现所推动的，例如 Intra-Cellular Therapies 的 ITI-007 和 Alkermes 的 ALKS-3831。然而，思觉失调症治疗领域存在大量未满足的需求。由于缺乏对确切疾病机制的了解，突破性治疗方法的发现受到阻碍。因此，需要创新药物传递技术来治疗这种使人衰弱的疾病。

思觉失调症药物市场报告亮点

  • 到2023年，第二代抗精神病药物将占据最大的市场销售份额，达到73.0%。思觉失调症药物市场对第二代抗精神病药物的需求正在增加，因为与第一代抗精神病药物相比，第二代抗精神病药物的安全性和有效性得到了改善。
  • 2023年，注射型抗精神病药物治疗领域占最大的市场销售份额。对注射型抗精神病药物的需求正在上升，因为它们可以解决与这种疾病相关的一些挑战。注射剂，尤其是长效注射剂 (LAI)，可稳定释放药物，有助于维持治疗药物水平并降低因错过剂量而导致復发的风险（这在口服药物中很常见）。
  • 2023年，医院药局领域占据最大的市场销售份额。医院药房能够提供全面的护理，包括管理复杂的药物治疗方案和监测副作用。
  • 北美思觉失调症药物市场占最大市场销售份额，2023年为39.0%。这是由于人们对思觉失调症和相关精神疾病的认识和诊断率提高。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章思觉失调症药物市场变项、趋势、范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 思觉失调症药物市场分析工具
    • 波特的分析
    • PESTEL分析

第四章思觉失调症药物市场：类别估计与趋势分析

  • 细分仪表板
  • 思觉失调症药物市场：类别变异分析，2023 年和 2030 年

第五章思觉失调症药物市场：治疗估计与趋势分析

  • 细分仪表板
  • 思觉失调症药物市场：2023 年和 2030 年治疗变异分析

第六章思觉失调症通路估算与趋势分析

  • 细分仪表板
  • 思觉失调症管道变化分析

第七章思觉失调症药物市场：区域估计与趋势分析

  • 2023 年及 2030 年思觉失调症药物市场占有率（按地区）
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Johnson &Johnson
    • Bristol-Myers Squibb/Otsuka Pharma
    • AstraZeneca
    • Sumitomo Dainippon
    • Eli Lilly &Company
    • Alkermes
    • Vanda Pharma
    • Allergan
    • Pfizer
    • H. Lundbeck A/S
简介目录
Product Code: GVR-2-68038-222-8

Schizophrenia Drugs Market Growth & Trends:

The global schizophrenia drugs market size is expected to reach USD 11.20 billion by 2030, registering to grow at a CAGR of 5.3% from 2024 to 2030 according to a new report by Grand View Research, Inc. The schizophrenia market is anticipated to be collectively driven by improved drug delivery technologies, availability of Long-Acting Injectables (LAIs) and increase in patients seeking treatment. The major features assisting uptake of novel drugs would be fast onset of action, accessibility to patients, efficiency and high patient compliance.

Schizophrenia imposes substantial burden on patients, their families and the overall society. Increasing awareness among patients and physicians in the field of mental health, particularly schizophrenia is likely to increase the penetration of these drugs in the market. Currently, second and third-generation antipsychotics capture significant market share. Pipeline drugs, undergoing clinical trials intend to block specific subtypes of serotonin and dopamine receptors which would help minimize the symptoms, modulate increased dopamine levels and further improve memory.

The growth in schizophrenia market is anticipated to be primarily driven by the arrival of late-stage pipeline products, such as Intra-Cellular Therapies' ITI-007 and Alkermes' ALKS-3831 which are directed towards the treatment of negative symptoms; however, there are significant unmet needs in the schizophrenia treatment space. Poor understanding about the exact disease mechanism remains, preventing the discovery of a therapeutic breakthrough. Hence, there is a need for innovation in drug delivery technologies for the treatment of this debilitating disorder.

Schizophrenia Drugs Market Report Highlights:

  • The second-generation-antipsychotics held the largest market revenue share of 73.0% in 2023. The demand for second-generation antipsychotics in the schizophrenia drugs market is rising due to their improved safety and efficacy profiles compared to first-generation antipsychotics.
  • The injectable antipsychotics treatment segment held the largest market revenue share in 2023. The demand for injectable antipsychotics is on the rise due to their ability to address several challenges associated with the condition. Injectable formulations, particularly long-acting injectables (LAIs), provide a steady release of medication, which helps maintain therapeutic drug levels and reduces the risk of relapse due to missed doses-a common issue with oral medications.
  • The hospital pharmacies segment held the largest market revenue share in 2023. Hospital pharmacies are well-positioned to provide comprehensive care, including managing complex medication regimens and monitoring side effects, which are critical for this condition.
  • North America schizophrenia drugs market held the largest market revenue share of 39.0% in 2023. It is attributable to the rising awareness and diagnosis rates of schizophrenia and related mental health disorders.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Schizophrenia Drugs Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Schizophrenia Drugs Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Schizophrenia Drugs Market: Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Schizophrenia Drugs Market: Class Movement Analysis, 2023 & 2030 (USD Million)
    • 4.2.1. Second-Generation Antipsychotics
      • 4.2.1.1. Second-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.2. Risperdal (Risperidone)
        • 4.2.1.2.1. Risperdal (Risperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.3. Invega (Paliperidone)
        • 4.2.1.3.1. Invega (Paliperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.4. Zyprexa (Olanzapine)
        • 4.2.1.4.1. Zyprexa (Olanzapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.5. Geodon (Ziprasidone)
        • 4.2.1.5.1. Geodon (Ziprasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.6. Seroquel (Quetiapine)
        • 4.2.1.6.1. Seroquel (Quetiapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.7. Latuda (Lurasidone)
        • 4.2.1.7.1. Latuda (Lurasidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.8. Aristada (Aripiprazole Lauroxil)
        • 4.2.1.8.1. Aristada (Aripiprazole Lauroxil) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.9. Fanapt (Iloperidone)
        • 4.2.1.9.1. Fanapt (Iloperidone) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.10. Saphris (Asenapine)
        • 4.2.1.10.1. Saphris (Asenapine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.1.11. Vraylar (Cariprazine)
        • 4.2.1.11.1. Vraylar (Cariprazine) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2. Third-Generation Antipsychotics
      • 4.2.2.1. Third-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 4.2.2.2. Abilify (Aripiprazole)
        • 4.2.2.2.1. Abilify (Aripiprazole) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.3. Others
    • 4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.2. First-Generation Antipsychotics
      • 4.3.2.1. First-Generation Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.3.3. Generics
      • 4.3.3.1. Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Schizophrenia Drugs Market: Treatment Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Schizophrenia Drugs Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
    • 5.2.1. Oral Antipsychotics
      • 5.2.1.1. Oral Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. Injectable Antipsychotics
      • 5.2.2.1. Injectable Antipsychotics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Schizophrenia Drugs Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Schizophrenia Drugs Market: Distribution channel Movement Analysis, 2023 & 2030 (USD Million)
    • 6.2.1. Hospital Pharmacies
      • 6.2.1.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. Retail Pharmacies
      • 6.2.2.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Online Pharmacies
      • 6.2.3.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Others
      • 6.2.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Schizophrenia Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Schizophrenia Drugs Market Share, By Region, 2023 & 2030 (USD Million)
  • 7.2. North America
    • 7.2.1. North America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. China
      • 7.4.2.1. China Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Japan
      • 7.4.3.1. Japan Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Australia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Saudi Arabia
      • 7.6.2.1. Saudi Arabia Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. UAE
      • 7.6.3.1. UAE Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. South Africa
      • 7.6.4.1. South Africa Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Schizophrenia Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Johnson & Johnson
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Bristol-Myers Squibb/ Otsuka Pharma
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. AstraZeneca
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Sumitomo Dainippon
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Eli Lilly & Company
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Alkermes
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Vanda Pharma
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Allergan
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Pfizer
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. H. Lundbeck A/S
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives